[Treatment of migraine: an update]

Over 12% of the population suffer from migraine, and though it can be incapacitating, the condition is too often minimized. The hidden costs of the disability, measured in terms of lost of productivity, are considerable. However, when treated correctly, the patient's quality of live can improve immensely, thus avoiding the tendency of leading to chronic daily headache (CDH) often associated with analgesic overuse. The availability of new treatments means that attacks can be targeted more specifically: the triptans, the latest, in Switzerland, being rizatriptan and eletriptan, offer different advantages with different constraints. Of particular importance, the maximum dose and the interval between doses must be scrupulously followed. At the same time, new developments in the prophylactic treatment of migraine show encouraging results, in particular the anti-epilectic drugs such as gabapentin and topiramate.